Minretumomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | TAG-72 |
| Clinical data | |
| Other names | CC49 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
  (what is this?) (verify) | |
Minretumomab (CC49) is a mouse monoclonal antibody[1] that was designed for the treatment of cancers that express the TAG-72 antigen. This includes breast, colon, lung, and pancreatic cancers.[2][3] Apparently, it never got past Phase I clinical trials for this purpose.[4]
Derivatives
A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]
Radiopharmaceuticals
Iodine (125I) minretumomab is an iodine-125 radiolabelled derivative that was developed for the detection of tumours in radioimmunoassays such as CA 72-4.[8]
Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (131I) and lutetium (177Lu) minretumomab, for example, were shown to induce human anti-mouse antibodies; no tumour response was observed in Phase I and II clinical trials.[5]
References
- ^ WHO Drug Information.
- ^ TAG-72 antigen entry in the public domain NCI Dictionary of Cancer Terms.
- ^ Scott, Andrew M.; Wolchok, Jedd D.; Old, Lloyd J. (2012). "Antibody therapy of cancer". Nature Reviews Cancer. 12 (4): 278. doi:10.1038/nrc3236. PMID 22437872.
- ^ CC49 on ClinicalTrials.gov.
- ^ a b Trahan Rieger, Paula, ed. (2001). Biotherapy (2nd ed.). Jones and Bartlett. pp. 334–335. ISBN 0-7637-1428-3.
- ^ Milenic, D. E.; Brady, E. D.; Garmestani, K.; Albert, P. S.; Abdulla, A.; Brechbiel, M. W. (2010). "Improved efficacy of α-particle-targeted radiation therapy". Cancer. 116 (4 Suppl): 1059–1066. doi:10.1002/cncr.24793. PMID 20127951.
- ^ Alderson, R. F.; Toki, B. E.; Roberge, M.; Geng, W.; Basler, J.; Chin, R.; Liu, A.; Ueda, R.; Hodges, D.; Escandon, E.; Chen, T.; Kanavarioti, T.; Babé, L.; Senter, P. D.; Fox, J. A.; Schellenberger, V. (2006). "Characterization of a CC49-Based Single-Chain Fragment−β-Lactamase Fusion Protein for Antibody-Directed Enzyme Prodrug Therapy (ADEPT)". Bioconjugate Chemistry. 17 (2): 410–418. doi:10.1021/bc0503521. PMID 16536473.
- ^ Guadagni, F.; Roselli, M.; Cosimelli, M.; Spila, A.; Cavaliere, F.; Tedesco, M.; Arcuri, R.; Abbolito, M. R.; Casale, V.; Pericoli, M. N.; Vecchione, A.; Casciani, C. U.; Greiner, J. W.; Schlom, J. (1996). "Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72-4 immunoassay". Cancer Research. 56 (22): 5293–5298. PMID 8912871.